The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies.
The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies.
复制标题
DOI：
10.1245/s10434-018-6379-8
复制
发表时间：
2018-07
影响因子：
3.7
通讯作者：
Wargo JA
中科院分区：
文献类型：
--
作者：
Keung EZ;Ukponmwan EU;Cogdill AP;Wargo JA
通过使用免疫疗法治疗癌症已经取得了前所未有的进展，现在FDA批准了几种药物用于癌症类型的广泛转移性疾病。免疫检查点阻断代表了一类特别有前途的药物，其阻断T细胞表面上的抑制性分子-导致其激活和免疫应答的传播。用这些药物治疗可以重新激活抗肿瘤免疫力，从而产生治疗反应，目前正在研究这些药物在辅助治疗中的应用。此外，它们在高风险可切除疾病的新辅助治疗中的使用有很强的理由（例如在黑色素瘤的情况下，在区域淋巴结疾病的情况下）。这是基于这些患者的复发风险相对较高，以及科学证据表明，与微转移性疾病的治疗（如辅助治疗）相比，完整肿瘤治疗（即新辅助治疗）的长期免疫记忆和肿瘤控制可能优于上级治疗。本文将讨论这种方法的潜在优势以及新辅助免疫检查点阻断的当前前景，以及在考虑这种策略时应考虑的警告。
There have been unprecedented advances in the treatment of cancer through the use of immunotherapy, with several agents now FDA-approved for use in widespread metastatic disease across cancer types. Immune checkpoint blockade represents a particularly promising class of agents that block inhibitory molecules on the surface of T cells - resulting in their activation and propagation of an immune response. Treatment with these agents may reinvigorate anti-tumor immunity resulting in therapeutic responses, and use of these agents is now being studied in the adjuvant setting. Additionally, there is a strong rationale for their use in the neoadjuvant setting for high-risk resectable disease (such as in the setting of regional nodal disease in the case of melanoma). This is based on the relatively high risk of relapse in these patients, as well as scientific evidence suggesting that long-term immunologic memory and tumor control may be superior in the setting of treatment with an intact tumor (i.e. neoadjuvant therapy) as opposed to treatment in the setting of micrometastatic disease (as in the setting of adjuvant treatment). Potential advantages of this approach as well as the current landscape for neoadjuvant immune checkpoint blockade will be discussed herein, as will caveats that should be considered in contemplating this strategy.
登录
查看更多内容
DOI：
10.1056/nejmoa1003466
发表时间：
2010-08-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者：
Urba WJ
影响因子：
28.2
作者：
Chen PL;Roh W;Reuben A;Cooper ZA;Spencer CN;Prieto PA;Miller JP;Bassett RL;Gopalakrishnan V;Wani K;De Macedo MP;Austin-Breneman JL;Jiang H;Chang Q;Reddy SM;Chen WS;Tetzlaff MT;Broaddus RJ;Davies MA;Gershenwald JE;Haydu L;Lazar AJ;Patel SP;Hwu P;Hwu WJ;Diab A;Glitza IC;Woodman SE;Vence LM;Wistuba II;Amaria RN;Kwong LN;Prieto V;Davis RE;Ma W;Overwijk WW;Sharpe AH;Hu J;Futreal PA;Blando J;Sharma P;Allison JP;Chin L;Wargo JA
通讯作者：
Wargo JA
DOI：
10.1056/nejmoa1504030
发表时间：
2015-07-02
期刊：
The New England journal of medicine
影响因子：
--
作者：
Larkin J;Chiarion-Sileni V;Gonzalez R;Grob JJ;Cowey CL;Lao CD;Schadendorf D;Dummer R;Smylie M;Rutkowski P;Ferrucci PF;Hill A;Wagstaff J;Carlino MS;Haanen JB;Maio M;Marquez-Rodas I;McArthur GA;Ascierto PA;Long GV;Callahan MK;Postow MA;Grossmann K;Sznol M;Dreno B;Bastholt L;Yang A;Rollin LM;Horak C;Hodi FS;Wolchok JD
通讯作者：
Wolchok JD
影响因子：
158.5
作者：
Grossman, HB;Natale, RB;Crawford, ED
通讯作者：
Crawford, ED
影响因子：
64.8
作者：
BRUNET, JF;DENIZOT, F;GOLSTEIN, P
通讯作者：
GOLSTEIN, P